Cell therapy weekly: Ori Biotech launch cell and gene therapy platform after securing over US$100 million in Series B funding
This week: Ori Biotech launch cell and gene therapy platform after securing over US$100 million in Series B funding, Halo Labs unveils the release of new tools for protein and CGT development and FDA approves Andelyn Biosciences GMP plasmid DMF for faster gene therapy development.
The news highlights:
- Ori Biotech launch cell and gene therapy platform after securing over US$100 million in Series B funding
- Halo Labs unveils the release of new tools for protein and CGT development
- FDA approves Andelyn Biosciences GMP plasmid for faster gene therapy development
Ori Biotech launch cell and gene therapy platform after securing over US$100 million in Series B funding
Ori Biotech (London, UK), an innovator in cell and gene therapy (CGT), has revealed that they have acquired over US$100 million in Series B funding from new and existing investors, including Novalis Life Sciences (NH, USA), Puhua Capital (Hangzhou, China) and Chimera Abu Dhabi (Abu Dhabi, UAE). The news brings great potential for the CGT manufacturing platform, promising the expansion of key personnel across all functions and allowing rapid transition through pre-commercialization to market launch.
The Ori manufacturing platform aims to fully automate CGT manufacturing to ensure seamless transition from pre-clinical process discovery, through to clinical trials and commercialization. Their vision is to increase throughput and reproducibility, all while enhancing quality and reducing expenditures.
“We view Ori Biotech as the best-in-class solution to solve many of the significant challenges now facing CGT researchers and developers”, stated Paul Meister, partner at Novalis LifeSciences.
Halo Labs unveils the release of new tools for protein and CGT development
Halo Labs (CA, USA), a venture-backed life science instrumentation company, has announced the launch of their latest tools – Aura+ and AuraPTx. The two instruments combine the use of background membrane imaging (BMI) and fluorescence membrane microscopy (FMI) to precisely identify the exact contents of your formulation.
“Developing best-in-class instruments that are highly focused on the needs of specific markets is what we do,” commented Rick Gordon, CEO of Halo Labs.
Aura PTx will allow drug product researchers to accurately detect excipient degradation, while Aura+ is a drug product quality solution that will ensure safety, stability and efficacy of protein and CGT.
FDA approves Andelyn Biosciences GMP plasmid DMF for faster gene therapy development
Andelyn Biosciences (OH, USA), a biopharmaceutical CGT contract development and manufacturing company has announced that their GMP plasmid DNA drug master file (DMF) has been approved by the US FDA. The approval allows organizations to vertically incorporate clients into the manufacturing procedure. This has the potential to condense the lengthy end-to-end manufacturing process from approximately 18 months, down to a swift 3 months.
“For Andelyn, 18 months is too long to deliver the life-saving promise of gene therapies to patient populations with unmet medical needs,” Wade Macedone, COO of Andelyn Biosciences, explained. “Andelyn’s mission is to enable gene therapy developers to deliver therapeutics to patients much faster, and developers working with us can now begin commercial manufacturing in just three months.”
You might also like:
